Ariel Roguin

🚨 Cardiology dogma says plaque only builds. It never breaks down. Nine imaging trials from 2004 to 2023 prove that dogma wrong. "But the data says otherwise." And no, this is not just theory. This is IVUS, OCT, and NIRS imaging inside real coronary arteries. I am a cardiologist. I have hundreds of patients on aggressive LDL-lowering therapy, and I track their numbers against this exact body of evidence. 🩺 Here is what the science actually says. 🔬 REVERSAL (2004): High-dose atorvastatin (LDL 79) halted plaque progression. Moderate pravastatin (LDL 110) let plaque grow +2.7%. Intensity at the artery wall matters. ✅ ESTABLISH (2004): Atorvastatin started immediately post-heart attack produced -13.1% plaque volume in 6 months. The fastest regression ever documented. ✅ ASTEROID (2006): Rosuvastatin drove LDL from 130.4 to 60.8 mg/dL. 63.6% of patients regressed. First frank proof reversal is real. ✅ SATURN (2011): 1,039 patients. Max-dose statins regressed plaque regardless of brand. Regression is a class effect of intensive LDL lowering. ✅ PRECISE-IVUS (2015): Adding ezetimibe to a statin nearly quintupled regression, 78% of patients regressed versus 58% on statin alone. ✅ GLAGOV (2016): Evolocumab drove LDL to 36.6 mg/dL. Regression correlated linearly down to LDL 20 mg/dL. No plateau. No floor. ✅ HUYGENS (2022): Evolocumab post-heart attack (LDL 28.1) nearly doubled fibrous cap thickening. ApoB below 65 mg/dL predicted nearly double the structural benefit. ✅ PACMAN-AMI (2022): Alirocumab (LDL 23.6) achieved triple regression, volume, lipid core, and cap thickness together. Event rate dropped to 8.3% versus 18.2% in non-regressors. ✅ YELLOW III (2023): Evolocumab cut dangerous thin-cap plaques from 48% to 13% in just 26 weeks. But 20% of patients did not respond despite LDL in the 30s and 40s. That matters because LDL lowering is necessary but not always sufficient. 🫀 A patient who gets LDL below 50, gets ApoB below 65, and starts therapy immediately after a cardiac event can show measurable plaque regression within 6 months. That is the difference between a plaque that ruptures and a plaque that heals. ❤️ Bottom line: Plaque is not a one-way street. It is not permanent once it forms. Over 4,000 patients across these trials prove regression is real, reproducible, and dose-dependent. Stop targeting LDL of 100. Stop treating 70 as aspirational. Measure ApoB. Target below 65 mg/dL. Drive LDL below 60, then below 50, then below 40, with no floor yet identified for benefit or harm. The question is no longer whether plaque can reverse. The question is why more clinicians are not treating it that way. What is your LDL and ApoB right now? #Cardiology #HeartDisease #HeartHealth #CardiovascularHealth #ApoB #Statins #PCSK9Inhibitors #Lpa #PreventiveCardiology #LifestyleMedicine